Faye instead chose a host of alternative approaches. After several months and more complications, she finally sought treatment at SDC. An endometrial biopsy now showed positive indications of a type of uterine CANCER called squamous cell carcinoma. She showed no mycoplasma involvement, however. Dr. Muñoz suggested that she consider surgery to remove the mass, with alternative therapy to follow. Faye refused to have the surgery.

She started on cesium for alkalinization and immunotherapeutic treatment using Mistletoe, the immune stimulators Utilin and Pind-avi, and the Biological Response Modifier Factor AF-2. She was also given thymus, liver, and spleen proteins. And she spent a week on a wheatgrass diet at the Optimal Health Institute.
 

Ultimately, Faye received NDV vaccine as an immunotherapeutic agent applied directly (topically) to the cervix. It would seem that the NDV had the effect of either killing or modifying the CANCER cells, or it provided a strong "antigenic target" so that Faye's immune system could kill the cells. It's also possible that all of these effects occurred.

Three months later, a Pap test showed no evidence of CANCER. Faye's treatment was continued until December, and then a CT scan was performed. This, too, showed no evidence of disease. A subsequent biopsy and other clinical findings came back negative for CANCER cells. Faye's status was complete remission. At her last checkup in February, her remission status was reconfirmed .

SDC is given the capacity to detect and stage CANCERs such as Faye's through the skill of Dr. Muñoz and the team at the clinic biolab. The clinicians and lab researchers work closely together, exchanging ideas and discussing up-to-date techniques for diagnosing and managing their patients' conditions.
 

Specialized diagnostic methods include CT scan, magnetic resonance imaging (MRI), ultrasound, CANCER markers, hair and urine analysis for heavy metals, and darkfield microscopy.

Quality of life and oncotherapy

While certain conventional modalities are said to have advanced in the last decade, conventional science is clearly not "winning the war" against CANCER. In fact, studies of 5-to-10 year patient survival rates show the failures of conventional oncotherapy. Still, quantity of life is only one issue. The quality of life for persons being treated for CANCER or other serious conditions is so very important. Ask them and they'll tell you what a difference it makes that alternative and complementary medicine aims to preserve the quality of life.

SDC's CANCER treatment program was developed by Dr. Muñoz. He says that, while traditional scientists tackle CANCER by screening thousands of compounds in the lab -- hoping to come across one that kills malignant tumor cells more efficiently than it kills normal growth -- he comes from the opposite direction: "First understand what's wrong inside the CANCERous cell; then design a medicine or treatment that corrects just that." His approach has paid off. He and his clinic team offer individually-designed treatment programs that reverse CANCER and other degenerative diseases in most instances.
 

What Is Anti-Mycoplasma  Immunotherapy?    Researchers long ago observed that when the immune system is weakened,  CANCER rates rise. A healthy immune system acts to destroy invaders and  "nonself" substances. But a weakened immune system can fail to make  the distinction between "self" and "nonself," and is thought to be responsible  for the initiation and progression of CANCERs (when CANCER cells aren't recognized  as nonself), and for autoimmune diseases (when self is identified as nonself).  Immunotherapies such as anti-mycoplasma vaccine help the body recognize  nonself substances and harmful microorganisms.   Normal healthy blood cells as seen under the darkfield microscope    Practitioners at SDC have seen evidence that mycoplasma are highly active in  80% of their CANCER patients and are also involved in the autoimmune process,  playing a role in conditions such as rheumatoid arthritis.    Mycoplasma are  extremely small, parasitic microorganisms that have no cell walls and are  pleomorphic (form-changing). Present in relatively benign forms  in everyone, they exist in pathogenic (disease-causing) forms in the blood of  many persons with CANCER and other degenerative diseases. These "stealth  pathogens" are often able to evade neutralization by the immune system.    The forms mycoplasma take and the extent of damage they do to blood cells  correlate with the stage of a CANCER or other disease. Their disease-causing  effects are best observed through a darkfield microscope, an instrument used  to examine live blood cells. Called the Platelet Culture Test, this study allows  one to observe changes in the blood that are either predictive of or evidence of disease.  Very abnormal, disregulated blood cells parasitized by mycoplasma.    Disease identification involves conclusions drawn from observing several  factors in the blood culture: the death rates of platelets (see Quick Definition);  the direct effect of mycoplasma on platelet shapes; the structure of the  remnants of mycoplasma activity; and the effects of mycoplasma on white  and red blood cells.   "In examining the relevant factors," says Filiberto Muñoz, M.D.,     "I can make early identification of forms typical of many CANCERs and illnesses.    "Dr. Muñoz has extensive experience in mycoplasma detection and treatment.    He worked with Werner Scheidl, H.M.D., of Germany, a pioneer in detecting the  presence of mycoplasma on the surface of platelets and the originator of the platelet test.    Whatever the disease implications of mycoplasma, these quickly-evolving  pleomorphsmake impossible targets for antibiotic treatment, leaving only  immune-stimulating vaccines produced from a patient's own blood as an effective  defense.       The Anti-Mycoplasma Autologous Vaccine (Myc-Vacc) was originally developed in  Germany. (Autologous means produced from oneself.) The Myc-Vacc is prepared  by drawing a sample of a patient's blood, isolating and culturing harmless mycoplasmic substances, and purifying the extract for re-injection. The vaccine's purpose is to  enhance and strengthen the immune system so that it is able to reverse the disease  process.   "By giving a patient benign mycoplasmic substances through a Myc-Vacc,"     Dr. Muñoz explains, "we are forcing the patient's immune system to recognize the  presence of disease-causing mycoplasma. In essence, the vaccine trains the immune system to attack mycoplasmic substances, which puts the stealth pathogens back into  balance as benign forms."   Dr. Scheidl believes the incidence of CANCER could be cut by 50% if people were to use this anti-mycoplasma therapy as a disease preventive.

Reversing breast CANCER

The reversal of breast CANCER is another challenge. By the time Sherry A., age 53, consulted Dr. Muñoz, it was fourteen months after her diagnosis of infiltrating ductile carcinoma. Her conventional oncologist had recommended a complete mastectomy, but Sherry had declined even a lumpectomy, opting instead for alternative treatments such as detoxification, supplements, and testosterone hormone blockers.

She says, "As a nurse, I knew from experience that the conventional therapy of chemo, radiation, and surgery wouldn't work. Over and over I'd seen them fail. Chemo and radiation actually impair the immune system. So I was left with the question, how could I fight CANCER with an impaired immune system? The conventional radiologists I went to told me I only had a short time left. I just wasn't willing to accept that. I turned to my faith for the courage to go beyond the conventional medicine I was familiar with."

Sherry came to SDC in June 1997. Her breast tumor had already grown too much for a lumpectomy. Dr. Muñoz put her on a program combining immunotherapy with chemo from her conventional oncologist. The SDC biolab then began to prepare an Anti-Mycoplasma Vaccine, and she was immediately given Mistletoe, and the immune stimulators Pind-avi and thymus protein. She went through two cycles of low-dose chemotherapy.

Within six months, Sherry's tumor had shrunk by 70%. Still, the CANCER had been so advanced that she agreed to the oncologist's recommendation of a mastectomy in January 1998. After surgery, she continued immunotherapy at SDC and remained stable. Then, in June 1998, despite Dr. Muñoz' warning that it might reactivate the tumor, she had a biopsy of a lymph node in her neck to check for metastasis. Almost immediately, several malignant nodules appeared in her lymph nodes and along her surgical scar. In February 1999, blood examination by darkfield microscopy revealed lingering mycoplasma infection. A second Myc-Vacc was prepared and administered.

Neo-Springer Vaccine

But there were still lingering fears of potentially dangerous CANCERs remaining along the surgical scar line and lymph nodes. So Sherry opted for Dr. Muñoz' recommendation of Neo-Springer Vaccine. SDC physicians have had success using this safe and effective version of the Springer anti-CANCER vaccine combined with other therapies. The original vaccine was produced by the late Georg Springer, M.D., the German scientist and physician who showed that two proteins on the surfaces of CANCER cells, called T antigen and Tn antigen, can be recognized by the immune system. He developed his vaccine to stimulate T/Tn antigen recognition and trigger CANCER-cell killing activity.

Sherry says, "In only a matter of weeks after receiving the vaccine, the dangerous lumps on my breast and lymph node swelling receded. I was overjoyed. At my next regular visit to my oncologist in July, she said this was amazing. She'd never seen anything like it before." Sherry continues immunotherapy as a precaution. But she is clear of CANCER.

Reversing other diseases

In addition to CANCER, the clinic offers a number of approaches to reversing other degenerative diseases. Some of these therapies, including Myc-Vacc and Transfer Factor, for example, are used in treating CFS, Candidiasis, MS, arthritis, lupus, and other conditions. Generally, new patients with diagnoses ranging from CFS to Parkinson's are checked for mycoplasma.

Dr. Sands says the SDC research team has developed a product called Cerasomal cis-9-cetyl myristoleate (CMO) that has been especially effective for the pain and inflammation of osteoarthritis and rheumatoid arthritis. This product, an oral form of CMO, is the cerasomal form of cetyl myristoleate. Significantly, it has a high level of bioavailability, whereas a free-cetyl myristoleate form is not highly bioavailable in oral form.

Elena G., age 38, was in nearly constant pain in both knees. She had resorted to codeine and aspirin for relief, but her symptoms were worsening. She came to see Dr. Sands after hearing about this "one-time therapy that brings a complete and permanent remission." An exam confirmed that Elena had osteoarthritis but was in good health otherwise.
 

Elena was told to refrain from alcohol, caffeine, and chocolate consumption for a month, and to take four CMO capsules daily for fifteen days.

"I started to feel better the second day," Elena said. "I couldn't believe it was the CMO until a week later when I found that the pain and inflammation were completely gone." Her four-week follow-up exam confirmed her remission: completely unrestricted movement and no inflammation.

Curing rheumatoid arthritis

Unlike Elena's straightforward progress, cases of rheumatoid arthritis such as Guadalupe C.'s are complex. Guadalupe, only age 29 when she came to SDC in January 1999, had been diagnosed with this usually debilitating condition in 1992. Her hands were deformed and she had difficulty walking. She says she couldn't even drive a car and had severe pain in her hands, elbows, and hips. She tested positive for rheumatoid factor and showed significant mycoplasma. Dr. Sands says, "Experience has taught us that treating severe arthritis--and many other diseases--is futile as long as high mycoplasma levels remain."

While Guadalupe's Myc-Vacc was being prepared, she was started on CMO capsules, chelation, and Allergo-Stop injections. Allergo-stop is a non-toxic treatment that works against the auto-antibodies normally present in the blood of patients with autoimmune disorders. It stimulates the immune system to produce normal antibodies by blocking and destroying the bad antibodies that cause the disease.
 

 The following month when Guadalupe returned to the clinic, physicians saw marked improvement. She could walk without discomfort and had much less pain in her hips. Her hand inflammation had also decreased. In July, Allergo-Stop treatment was repeated, and glucosamine and chondroitin sulfate were added for two months to help regenerate cartilage. By September, she was free of pain and inflammation. After finishing Allergo-Stop treatment, she was tested and found to be in remission. CMO was continued to prevent further autoimmune attacks. At her final checkup in December 1999, Guadalupe was found to be continuing in full remission.

Natural therapies

SDC's general treatment program uses sophisticated natural therapies. This program involves detoxification and revitalization to achieve better distribution and dissemination of therapies to fight CANCER and other conditions. Included are intravenous (IV) infusions of chelation therapy; high IV doses of vitamin C, minerals, essential amino acids, and multi-vitamins; and strong nutritional and supplemental programs. No single approach is applied in isolation and all treatment programs are individualized.

Each patient at SDC is monitored closely by clinic physicians and nurses. Former patient Faye L. says, "I continue to have regular follow-up checkups. Dr. Muñoz makes sure of that. . . . I have never known a more caring and devoted physician. I thought I was special, but so is every other patient he works with."

Understandably, a diagnosis of CANCER or other degenerative disease is difficult, often frightening. This is why the extensive clinical experience and research skill of the SDC staff--combined with their belief in "curing the incurable"--are so important.

Contact: